Helmy Haja Mydin’s Post

Interesting cases using 18F-FAPI-74 Nouzha WiNMI leader,Group Expert of WiN Global EANM_WE,Vp #WiN Global,#WiNMI,#WiN for peace,#WiN YG,#WiN Africa,#WiN IAEA,#WiN France,#WiN Europe,#AMMN ,#SNMMI,#PSNM,#AI,#Nuclear Medicine,#Oncology,#Molecular Imaging,#Myocardial imaging,#ASCO,#EANM,#EANM_WE,#EANM_WE, #WARMTH, #alpha Therapy, #beta Nuclear Medicine therapyVp,#Oncidium,#ESMIT,#SFMN,#UCLA,#EJNMMI,#Americanoncologyinstitute,#Urology,#Prostate cancer,#CEA,#INSTN,#Clinical Nuclear Medicine ,#Endocrinology,#Parathyroid

Researchers have been able to better identify the different subtypes of #nccRCC to provide effective treatment, which was the focus of a presentation by Laurence Albiges, MD, PhD, during #KCRS24. https://lnkd.in/edZ8tkr7

🔬 Check out this research from Elizabeth R. Plimack, MD, MS, FASCO, and colleagues which analyzed #mutations and pathologic complete response in patients with #MIBC. 🧠 Learn More:

🐁 Want to enhance your confidence in choosing the optimal immune humanization technique (CD34+ HSCs or PBMCs) for your research question? Join our webinar Feb 20 at 1 pm, ET, when JAX scientists will compare humanization strategies across NSG variants:

Curious about translational preclinical models? Join us on 20th Feb at 1pm EST to discuss humanized mouse models. #immunology #immunotherapy #immunooncology

NEW from #ASH2023 | Unmet needs in #hemophilia treatment 🎥 🩸 Glaivy Batsuli, MD, Stanford University, discusses challenges that remain in treating patients with #hemophilia She mentions the unmet need for patients with #hemophiliaB without #inhibitors and the importance of improving the quality of life for these patients 🔦 Give it a watch to learn more 👉 https://lnkd.in/ejms3ZFu #HemOnc American Society of Hematology

Try AgeLOC Cordyceps https://lnkd.in/g3h2DBW (Not ADD Pitch-FYI) https://lnkd.in/dXi5ZFWq 6 Benefits of Cordyceps, All Backed by Science

ICYMI, Dr. Caner Saygin & team's newest paper is AACR Journals can be found here: https://lnkd.in/gV-3m-pa It shows for the first time that CHIP can cause ALL & the importance of classifying & treating ALL with MyM differently-- key findings!

📚🚀 Excited to share that I've just published my first first-author publication! 🌟 Titled "Targeting the EGFR Pathway: An Alternative Strategy for the Treatment of Tuberous Sclerosis Complex?" Huge thanks to my co-authors and mentors especially Victoria-Elisabeth Gruber, Theresa Scholl and Martha Feucht for their invaluable guidance and support throughout this journey. 🙏🔬 Check out the full paper https://lnkd.in/gFrMNFWD and let's continue making strides together! 💡 #FirstAuthorPublication #MedUniVienna #Science #TuberousSclerosisComplex #SEGA #EGFRPathway 🎉

Our first iRhom2 paper on TOC oesophagus transcriptional dynamics